Locations:
Search
Novel three-drug regimen used to manage life-threatening developments
Momelotinib, a new JAK inhibitor, inches closer to market approval
Claims data reveal disorder is often overlooked and undertreated
Management options expand in both inpatient and outpatient settings
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Sudden-onset abdominal pain prompts urgent visit
Study reveals characteristics that may spark the development of myelodysplastic syndrome and acute myeloid leukemia
Novel regimen may help overcome the shortcomings of traditional chemotherapy in geriatric population
Follow-up study confirms safety and tolerability of new treatment protocol
Study finds drug safe and effective when combined with chemotherapy
Multidisciplinary team tackles the management of 84 uncommon cancers and blood disorders
Advertisement
Advertisement